# **UNIVERSITY** OF BIRMINGHAM University of Birmingham Research at Birmingham

# Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients

Larsen, Torben Bjerregaard; Rasmussen, Lars Hvilsted; Gorst-rasmussen, Anders; Skjøth, Flemming; Lane, Deirdre A.; Lip, Gregory Y.h.

DOI: 10.1016/j.amjmed.2014.07.023

License: Other (please specify with Rights Statement)

Document Version Peer reviewed version

#### Citation for published version (Harvard):

Larsen, TB, Rasmussen, LH, Gorst-rasmussen, A, Skjøth, F, Lane, DA & Lip, GYH 2014, 'Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study', The American Journal of Medicine, vol. 127, no. 12, pp. 1172-1178.e5. https://doi.org/10.1016/j.amjmed.2014.07.023

Link to publication on Research at Birmingham portal

#### **Publisher Rights Statement:**

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA,

Lip GYH, Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study, The American Journal of Medicine (2014), doi: 10.1016/j.amjmed.2014.07.023.

#### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

## Accepted Manuscript

Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study

Torben Bjerregaard Larsen, MD, PhD Lars Hvilsted Rasmussen, MD, PhD Anders Gorst-Rasmussen, MSc, PhD Flemming Skjøth, MSc, PhD Deirdre A. Lane, PhD Gregory Y.H. Lip, MD

PII: S0002-9343(14)00661-5

DOI: 10.1016/j.amjmed.2014.07.023

Reference: AJM 12624

To appear in: The American Journal of Medicine

Received Date: 9 July 2014

Revised Date: 10 July 2014

Accepted Date: 11 July 2014

Please cite this article as: Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GYH, Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study, *The American Journal of Medicine* (2014), doi: 10.1016/j.amjmed.2014.07.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Word count: 5,031 words (including title page, abstract, main text, tables and figures)

## Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients:

### A nationwide cohort study.

Torben Bjerregaard Larsen, MD, PhD<sup>1,2</sup>, Lars Hvilsted Rasmussen, MD, PhD<sup>2</sup>, Anders Gorst-Rasmussen, MSc, PhD<sup>1,2</sup>, Flemming Skjøth, MSc, PhD<sup>1,2</sup>, Deirdre A. Lane, PhD<sup>3</sup>, Gregory Y.H. Lip, MD<sup>2, 3</sup>

1. Department of Cardiology, Aalborg Atrial Fibrillation Study Group, Aalborg University Hospital, Denmark

2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.

3. University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

Running head: Dabigatran for secondary prevention of stroke in atrial fibrillation

Summary conflict of interest statements: Professor Lip has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola and Boehringer Ingelheim and has served as a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo and Sanofi Aventis. Dr Lane has received investigator-initiated educational grants from Bayer Healthcare and Boehringer Ingelheim and served as a speaker for Boehringer Ingelheim, Bayer Healthcare, BMS/Pfizer. In addition, DAL is on the Steering Committee of a Phase IV apixaban study (AEGEAN). Both Prof Lip and Dr Lane have participated in various clinical trials of stroke prevention in AF. Associate Professor Larsen has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim. Associate Professor Larsen and Professor Rasmussen have been on the speaker bureaus for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics and Boehringer Ingelheim. Other authors – none declared.

*Correspondence to:* Associate professor Torben Bjerregaard Larsen, MD, PhD. Department of Cardiology, Aalborg University Hospital, Søndre Skovvej 15, DK-9000, Denmark. tobl@rn.dk

#### Abstract

*Background* This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both 'new starters' on dabigatran and 'switchers' to dabigatran from warfarin.

*Methods* We identified in nationwide Danish registries 2,398 patients with atrial fibrillation and a history of stroke/TIA, making a first-time purchase of dabigatran 110mg bid (D110) and 150mg bid (D150). Patients were categorized as either vitamin K antagonist (VKA) naïve or experienced. Warfarin controls were identified using a complete (for VKA-naïve dabigatran patients) or matched sampling approach (for VKA-experienced dabigatran patients). Subjects were followed for an average of 12.6 months for stroke and transient ischemic attacks. Confounder-adjusted Cox regression models were used to compare event rates between treatments.

*Results* Among patients with a history of stroke/ transient ischemic attack and prior VKA experience, switching to dabigatran was associated with an increased stroke/ transient ischemic attack rate for both dabigatran doses compared to continuing on warfarin (D110 hazard ratio [HR] 1.99, 95% confidence interval [CI]: 1.42-2.78; D150 HR 2.34, 95% CI: 1.60-3.41).

Among prior stroke/ transient ischemic attack patients who were new starters on dabigatran or warfarin, the rate of stroke/ transient ischemic attack for both doses of dabigatran was similar to or lower than warfarin (D110 HR 0.64, 95% CI: 0.50-0.80; D150 HR 0.92, 95% CI: 0.73-1.15).

*Conclusions* In this register-based study, VKA-experienced patients with a history of stroke or transient ischemic attack who switched to dabigatran therapy had an increased rate of stroke compared to patients persisting with warfarin therapy.

**Keywords:** atrial fibrillation, stroke, antithrombotic therapy, dabigatran, warfarin, comparative effectiveness

Abbreviations: HR = hazard ratio; VKA = vitamin K antagonist

#### Introduction

The risk of stroke in atrial fibrillation patients is high, especially among patients with a history of ischemic stroke or transient ischemic attack<sup>1</sup>. Stroke prevention in atrial fibrillation has conventionally involved anticoagulant therapy with vitamin K antagonists (VKA) such as warfarin<sup>2</sup>, but a narrow therapeutic range makes optimal treatment challenging. Dabigatran etexilate is a direct thrombin inhibitor whose rapid and predictable response can mitigate the complexity of conventional anticoagulant therapy. Trials and subsequent observational studies in mixed patient populations have shown dabigatran to provide comparable or slightly improved protection against stroke and systemic embolism, without compromising bleeding safety<sup>3–5</sup>.

Trial-based findings within the clinically important subgroup of patients with prior stroke have been consistent with the overall efficacy and safety profile results for dabigatran. A predefined sub-study of the RE-LY study (Randomized Evaluation of Long Term Anticoagulant Therapy) found similar or slightly lower rates of stroke and systemic embolism among patients with a prior stroke/transient ischemic attack (2.78% for warfarin, 2.32% for dabigatran 110 mg bid; 2.07% for dabigatran 150 mg bid)<sup>6</sup>. In an indirect comparison of three new oral anticoagulants (apixaban, rivaroxaban and dabigatran) using secondary prevention (previous stroke) trial subgroups<sup>7</sup>, we found that dabigatran had similar efficacy to warfarin for stroke/systemic embolism, ischemic stroke, and all-cause mortality. However, the extent to which these trial-based subgroup findings transfer to a practical clinical setting is currently unclear.

Analysis of observational data, while insufficient for providing unequivocal treatment recommendations, can provide valuable insight into medication effectiveness in a practical clinical setting. The present nationwide observational study shares design and data similarities with recent studies on myocardial infarction and bleeding risk with dabigatran and warfarin, but in the present study we focus only on patients with previous stroke<sup>8,9</sup>. Specifically, we used prescription purchase data to assess the effectiveness of dabigatran relative to warfarin for secondary prevention in a real-world atrial fibrillation population with a history of stroke or transient ischemic attack. A substantial proportion of dabigatran initiators are patients who are switched from warfarin, so-called warfarin survivors<sup>10</sup>. In RE-LY, no differences were found in the prognosis between such warfarin survivors and new starters<sup>11</sup>. However, this finding may not transfer to a non-trial setting with more autonomous treatment management, particularly not in a high-risk patient group. Accordingly, we

separately within the stratum of 'switchers' from warfarin to dabigatran (compared to warfarin persisters); and within the stratum of 'new starters' on dabigatran (compared to new starters on warfarin).

#### Methods

We used the civil registration number assigned to all Danish residents to link three nationwide databases: (i) the Danish National Prescription Registry<sup>12</sup> which holds information on purchase date, Anatomical Therapeutic Chemical [ATC] classification code, and package size for every prescription purchase in Denmark since 1994; (ii) the Danish National Patient Register<sup>13</sup> established in 1977, which includes admission/discharge date, and discharge International Classification of Diseases [ICD] diagnoses for >99% of somatic hospital admissions in Denmark; and (iii) the Danish Civil Registration System<sup>14</sup> which holds information on sex, date of birth, vital and emigration status.

#### Study population

We identified first-time purchases of dabigatran 110mg bid (D110) or dabigatran 150mg bid (D150) during the period August 1, 2011 (dabigatran market entry in Denmark) to May 30, 2013, alongside all purchases of warfarin during the period August 1 2009 to May 30 2013 (incorporating predabigatran warfarin purchases in order to determine VKA-experience status). We excluded purchases not preceded by a hospital diagnosis of AF, or preceded by a hospital diagnosis of mitral stenosis, venous thromboembolism, or valvular surgery, or preceded by phenprocoumon use. In accordance with the focus on secondary prevention, we excluded purchases not preceded by a hospital diagnosis of stroke/ transient ischemic attack. A person was considered VKA-naïve, respectively VKA-experienced, if the time since the last warfarin purchase was  $\geq$ 2 years, respectively <2, years. A relatively long period was used in order to also reflect naivety in relation to treatment routine.

From the purchase data, we defined a VKA-naïve stratum of all VKA-naïve subjects making a firsttime purchase of dabigatran. As controls in this stratum, we sampled the full population of VKA-

naïve subjects making a first-time warfarin purchase. The baseline date in the VKA-naïve stratum was set to the date of first purchase.

We next defined a VKA-experienced stratum of all VKA-experienced subjects purchasing dabigatran for the first time (switchers). Comparable controls were selected for each switcher by matched sampling among VKA-experienced warfarin controls. Specifically, 2 VKA-experienced warfarin users were matched to each switcher according to calendar month of purchase and duration of VKA-experience (up to 1 year; 1-5 years; more than 5 years). The baseline date in the VKA-experienced stratum was set to the date of (first) purchase in the calendar month of inclusion.

#### Endpoints and variable definitions

Participants were followed until July 31 2013 in the Danish National Patient Register (using the 10th Revision of ICD codes, ICD-10) for the occurrence of the following endpoints: ischemic stroke (I63, I64.9) or transient ischemic attack (G45); and fatal stroke, not including hemorrhagic stroke (ischemic stroke or transient ischemic attack followed by death within 30 days).

Demographic data were obtained from the Danish Civil Registration System. Comorbidities and comedications (listed in Table 1) were ascertained from the Danish National Patient Registry and the Danish National Prescription Registry (for ICD-10 and ATC code definitions, see Supplementary Table 1). We combined covariate information into CHADS<sub>2</sub> (Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, and previous stroke or TIA)/CHA<sub>2</sub>DS<sub>2</sub>VASc (Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack, Vascular disease, Age 65–74 years, and Sex category [female gender]) scores <sup>15</sup> for assessing stroke risk, and a HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) bleeding risk score16 (definitions in Supplementary Table 2).

#### Statistical analysis

Time-to-event analysis was used to compare the risk of stroke/ transient ischemic attack between treatment groups within the two VKA-experience strata (naïve/experienced), measuring risk time from baseline and until the relevant event, emigration, death, or July 31 2013, whichever came first.

Crude cumulative incidences of stroke/ transient ischemic attack were calculated with the Aalen-Johansen method under competing risk of death<sup>15</sup>. Cox regression was used to contrast event rates between the dabigatran users and warfarin controls within each of the VKA-experience strata. To address confounding by indication of treatment, regression analyses were adjusted for the baseline values of the following indications: age (continuous; cubic spline); components of CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED (binary); and months since August 2011 (continuous; cubic spline). In the VKA-experienced stratum, we also adjusted for time since initiation of VKA therapy (continuous; cubic spline).

We estimated 3-month persistence probabilities<sup>15</sup>, defining time of non-persistence as the time of treatment switching or >30 days discontinuation (ascertained from previous package sizes and a standard daily dose).

A number of sensitivity/supplementary analyses were carried out. First, we repeated regression analyses after censoring individuals at the time of non-persistence in order to quantify the effect of continuous treatment (implicitly assuming censoring to be non-informative conditionally on baseline covariates). Second, to assess robustness to a more stringent endpoint definition (with presumably higher validity), regression analyses were also repeated when requiring endpoints to have been registered as the primary diagnosis in connection with hospitalization for at least one night. Lastly, we repeated a subset of the main analyses in the primary prevention group, i.e. the analogously defined two VKA-experience strata based on the subset of the warfarin/dabigatran purchase data that excluded subjects with a prior diagnosis of stroke/ transient ischemic attack.

Stata/MP version 12.1 was used for the statistical analysis. A two-sided P value <0.05 was considered as statistically significant.

#### Results

#### Study population characteristics

A flow chart of the study population is shown in Figure 1. In the VKA-naïve stratum, we included 1,439 patients with atrial fibrillation and a history of stroke/ transient ischemic attack making a first-time dabigatran purchase; alongside 1,825 patients making a first-time warfarin purchase (controls). In the VKA-experienced stratum, 959 dabigatran switchers where matched to 1,918 warfarin controls (selected among 11,159 unique subjects with a total of 76,553 purchases).

Baseline information is shown in Table 1. Within each of the VKA-experience strata, D110 users were older, with a median age over 80 (compared to median ages below 76 and 70 for warfarin, respectively D150 users). Accordingly, D110 users also had a higher stroke and bleeding risk (according to CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED scores). There were slightly more females than males in the D110 group (55% to 56%), but not in the D150 and the warfarin group (36% to 44% females). Comparing between VKA-experience strata, the age and gender distribution was similar for each of the three treatments. Patients in the VKA-experienced stratum generally had higher CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>VASc scores but a similar or slightly decreased HAS-BLED score. There were substantially fewer clopidogrel users in the VKA-experienced stratum (3.0% to 5.8%) compared the VKA-naïve stratum (20.1% to 21.4%) in the VKA-naïve stratum; and also fewer aspirin users users (21.8% to 23.0%) than in the VKA-naïve stratum (34.8% to 43.0%).

#### Stroke and transient ischemic attacks

The average follow-up time was 12.6 months (standard deviation: 4.5 months). Plots of crude cumulative incidences for the composite endpoint of stroke/ transient ischemic attack (Figure 2) showed that, in the VKA-naïve stratum, D110 users had the lowest risk and D150 the highest risk, with the risk increasing more rapidly in the early follow-up period. The stroke risk in the VKA-experienced stratum was lower overall compared to the VKA-naïve stratum: within this stratum, warfarin users had the lowest and D110 users the highest risk.

In the VKA-naïve stratum ('new starters'), crude annual event rates of stroke/ transient ischemic attack ranged from 14.0% to 20.0% (Table 2). For the composite endpoint stroke/TIA, adjusted event rates showed a significant 36% reduction among D110 users in compared to warfarin (hazard

ratio [HR] 0.64, 95% confidence interval [CI]: 0.50-0.80) but similar rates for D150 users (HR 0.92, 95% CI: 0.73-1.15). When investigating stroke and transient ischemic attack separately, similar results were found, with slightly larger rate reductions relative to warfarin for the endpoint transient ischemic attack. Crude annual rates of fatal stroke/ transient ischemic attack (not shown in Table 2) were generally low, ranging from 0.3% to 1.2%.

Turning to the VKA-experienced stratum ('switchers'), crude annual event rates of stroke/ transient ischemic attack were overall substantially lower than in the VKA-naïve stratum, ranging from 4.8% to 10.8% (Table 2). For stroke/TIA, we saw a significant doubling of the event rate of for both D110 and D150 compared to warfarin (D110 HR 1.99, 95% CI: 1.42-2.78; D150 HR 2.34, 95% CI: 1.60-3.41). When considering stroke and transient ischemic attack separately, comparably sized increases in adjusted rates for dabigatran relative to warfarin. There were again few fatal strokes/ transient ischemic attack (not shown in Table 2), with crude annual rates ranging from 0.2% for D150 (0.3% for warfarin), to 2.3% for D110.

#### Treatment persistence and supplementary analyses

Persistence probabilities at 3 months were 87% (warfarin), 79% (D110), and 82% (D150) in the VKA-naïve stratum; 91% (warfarin), 81% (D110), and 84% (D150) in the VKA-experienced stratum.

The persistence-adjusted Cox regression gave similar results as the main analysis (Supplementary Table 3); the increased rate of stroke/ transient ischemic attack with dabigatran relative to warfarin in the VKA-experienced stratum was slightly more pronounced in this analysis (D110 HR 2.33, 95% CI: 1.53-3.55; D150 HR 2.48, 95% CI: 1.53-4.02). Upon censoring patients at time of non-persistence, crude event rates in the VKA-naïve stratum were increased compared to the main analysis. The results of the second sensitivity analysis, featuring a more restrictive endpoint definition (Supplementary Table 4), were also consistent with the main analysis, although events rates were low.

Repeating regression analyses in the primary prevention group (Supplementary Table 5) lead to similar rates of stroke/ transient ischemic attack across strata in the adjusted comparison of D150 versus warfarin (VKA-naïve HR 0.98, 95% CI: 0.72-1. VKA-experienced HR: 0.83, 95% CI: 0.51-1.35). In contrast, the rate for D110 was increased compared to warfarin in the VKA-experienced stratum, but not in the VKA-naïve (HR 1.86, 95% CI: 1.30-2.67 and HR 1.01, 95% CI: 0.74-1.37,

respectively). Of note, the primary prevention group was substantially younger than the secondary prevention group; and with lower stroke and bleeding risks, according to the CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED scores, respectively (Supplementary Table 6).

#### Discussion

In this large register-based observational study of secondary stroke prevention among atrial fibrillation patients, we found similar effectiveness of dabigatran relative to warfarin for secondary prevention of stroke/ transient ischemic attack among 'new starters' on anticoagulant therapy. In contrast, we found a doubling of the stroke/ transient ischemic attack rate among 'switchers' to both dabigatran doses compared to persisters on warfarin. The overall stroke risk was generally higher in 'new starters' on anticoagulant therapy regardless of therapy. A supplementary analysis in the primary stroke prevention group indicated no differences in stroke risk relative to warfarin for both 'new starters' and 'switchers' on dabigatran, except for switchers to D110 who were at an increased risk of stroke/TIA.

Altogether, our study suggests that caution and vigilance is needed when switching prior VKAexperienced atrial fibrillation patients to dabigatran, especially for patients who are able to consistently maintain a high average time in therapeutic range. The extent to which the increased risk with dabigatran can be attributed to the intervention of switching is, however, not clear, particularly in the light of the findings from randomized trials. A predefined sub-study of RE-LY among participants with prior stroke/ transient ischemic attack found no significant difference between both dabigatran doses and warfarin in relation to the risk of stroke or systemic embolism<sup>16</sup>. Of note, there were several key differences from the present study: for example, prior VKA experience was not explicitly accounted for, participants were much younger, and recurrent stroke rates were lower. However, in the phase III trial on rivaroxaban versus warfarin<sup>17,18</sup>, a marked increase in cardiovascular events were seen during the transition to open label therapy for patients switching therapy at the end of the trial. Meta-analyses and indirect comparisons have thus far confirmed the non-inferiority findings from the RE-LY subgroup studies<sup>7,19</sup>. Divergent findings in an observational study necessitate caution since design limitations can easily induce spurious results. Bias due to residual or unmeasured confounding by indication is a serious concern: an apparent treatment effect may simply reflect unaccounted indications for which the treatment was

administered. In the present study, clinicians may have been more likely to switch patients with difficulties maintaining a high time in therapeutic range. Since INR measurements are not available from the registries, we were unable to investigate this. While confounding bias alone is a viable explanation for our findings, it does raise new questions about the sources of such confounding. Indeed, in our analyses, we adjusted for variables that a priori would be expected to be strong confounders, yet we observed only a modest change in the crude point estimates. If confounding bias were to completely explain our findings, we speculate that there would either have to be many unmeasured confounders with a moderate effect or a few very strong unmeasured confounders. As a crude, quantitative assessment, a binary unmeasured confounder with a prevalence of 80% among switchers and 20% among warfarin persisters would only completely explain a Cox model HR of 1.7 if the confounder triples the rate of stroke/ transient ischemic attack <sup>20</sup>.

A combination of confounding bias and (causal) effects due to treatment switching may also explain our divergent findings. Patients may be less protected in the early period following a switch from warfarin, for example because of 'latent' strokes previously prevented by warfarin and appearing after warfarin discontinuation - or simply because the patient is less familiar with the new treatment. Indeed, plots of crude incidences lend some support to the observation that the early period after switching is a higher risk period. Lastly, irrespective of whether or not our findings are partly attributable to drug-related causal effects, they still convey the important message that real world prior stroke/ transient ischemic attack 'switchers' from warfarin to dabigatran represent a high risk group. Our study may offer a valuable insight for a future randomized trial of outcomes after treatment switching.

We conclude by commenting on the overall stroke risk differences between VKA-naïve and VKAexperienced users which were clearly visible from Figure 2. These are likely to be attributable to the 'healthy user' selection inherent in the definition of the VKA-experienced stratum: to be included in the VKA-experienced stratum, one has to survive the time from treatment initiation to study inclusion with at most one stroke. The differences apparent in Figure 2 emphasize the appropriateness of treating the VKA-naïve and VKA-experienced stratum separately.

Limitations of the present observational study in terms of confounding bias have already been discussed, with the lack of INR measurements being a particular concern. Also, the accuracy of the proposed "intention-to-treat approach" relies on patients actually taking their drugs, as is the case for all comparative effectiveness studies. While the validity of an ischemic stroke diagnosis is high

in the Danish Registry of Patients<sup>21</sup>, misclassification is also a relevant limitation (reassuringly, a more stringent definition of endpoints lead to results consistent with our main analysis). Lastly, one should be aware of the limitations of a comparative effectiveness study of a newly-marketed drug such as dabigatran; these can include channeling of selected patient groups towards the new drug, as well as time-varying user population characteristics<sup>22</sup>. Strengths of the study include the use of large 'real world' atrial fibrillation population, the long follow-up period, and the completeness of the registries.

#### Conclusion

In this nationwide cohort study, we found that for patients with a history of stroke/ transient ischemic attack who are VKA-naïve, both dabigatran doses provided similar protection to warfarin against recurrent stroke/TIA. Among VKA-experienced patients, the risk of recurrent stroke/ transient ischemic attack was significantly increased compared to continued warfarin usage. Although clinical implications from observational data must be drawn carefully, our findings stress the importance of caution and vigilance when switching prior VKA-experienced atrial fibrillation patients to dabigatran, especially for patients with prior good quality anticoagulation as reflected by a high time in therapeutic range.

#### Contributors

TBL provided the idea for the article and contributed to drafting and subsequent revisions. LHR, AGR, DL and GYHL contributed to manuscript drafts and revisions. FS and AGR did the analyses and contributed to manuscript revisions. TBL and GYHL are the guarantors.

#### **Sources of Funding**

None.

#### Disclosures

Professor Lip has served as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola and Boehringer Ingelheim and has served as a speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo and Sanofi Aventis. Dr Lane has received investigator-initiated educational grants from Bayer Healthcare and Boehringer Ingelheim and served as a speaker for Boehringer Ingelheim, Bayer Healthcare, BMS/Pfizer. In addition, DAL is on the Steering Committee of a Phase IV apixaban study (AEGEAN). Both Prof Lip and Dr Lane have participated in various clinical trials of stroke prevention in AF.

Associate Professor Larsen has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim. Associate Professor Larsen and Professor Rasmussen have been on the speaker bureaus for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics and Boehringer Ingelheim. Other authors – none declared.

12

#### References

- 1. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GYH. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis. *Stroke*. 2013;44(5):1329–36. doi:10.1161/STROKEAHA.113.000883.
- 2. Banerjee A, Marín F, Lip GYH. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. *Stroke*. 2011;42(11):3316–22. doi:10.1161/STROKEAHA.111.617886.
- 3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009;361(12):1139–51. doi:10.1056/NEJMoa0905561.
- 4. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. *J Am Coll Cardiol*. 2013;61(22):2264–73. doi:10.1016/j.jacc.2013.03.020.
- 5. Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. *BMJ Open*. 2013;3(5):e002758. doi:10.1136/bmjopen-2013-002758.
- 6. Diener H-C, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. *Lancet Neurol*. 2010;9(12):1157–63. doi:10.1016/S1474-4422(10)70274-X.
- 7. Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GYH. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. *BMJ*. 2012;345(nov05 1):e7097. doi:10.1136/bmj.e7097.
- 8. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in "real world" patients with atrial fibrillation treated with dabigatran or warfarin. *Am J Med*. 2014;127(4):329–336.e4. doi:10.1016/j.amjmed.2013.12.005.
- 9. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GYH. Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation. *Am J Med*. 2014;127(7):650–656. doi:10.1016/j.amjmed.2014.01.031.
- 10. Lane DA, Lip GYH. Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. *Lancet Neurol*. 2010;9(12):1140–2. doi:10.1016/S1474-4422(10)70275-1.
- Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. *Circulation*. 2010;122(22):2246–53. doi:10.1161/CIRCULATIONAHA.110.973735.

- 12. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. *Scand J Public Health*. 2011;39(7 Suppl):38–41. doi:10.1177/1403494810394717.
- 13. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Health*. 2011;39(7 Suppl):30–33. doi:10.1177/1403494811401482.
- 14. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health*. 2011;39(7 Suppl):22–25.
- 15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18(6):695–706.
- Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. *Circulation*. 2012;126(20):2381–91. doi:10.1161/CIRCULATIONAHA.112.115410.
- 17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883–91. doi:10.1056/NEJMoa1009638.
- 18. Mahaffey KW, Hellkamp AS, Patel MR, et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. *Circ Cardiovasc Qual Outcomes*. 2013;6(4):470–8. doi:10.1161/CIRCOUTCOMES.113.000132.
- 19. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2012;5(4):480–6. doi:10.1161/CIRCOUTCOMES.112.965988.
- 20. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics*. 1998;54(3):948–63.
- 21. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. *Neuroepidemiology*. 2007;28(3):150–4. doi:10.1159/000102143.
- 22. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. *Clin Pharmacol Ther*. 2011;90(6):777–90. doi:10.1038/clpt.2011.235.

#### **Figure legends**

# Figure 1. Flow chart showing how the study population was obtained from prescription purchase data.

Boxes show number of purchases with number of unique subjects in parentheses. The final study population with prior stroke is displayed in dashed boxes. In the VKA-experienced stratum, warfarin purchasers were sampled in a 2:1 ratio for each switcher to dabigatran (according to calendar month of purchase and duration of VKA-experience).

Figure 2. Crude cumulative incidence of the composite endpoint of stroke or transient ischemic attack, according to Vitamin K antagonist-experience and current treatment.

Table 1. Participant characteristics at baseline, according to VKA-experience stratum and
current treatment.

	Vitamin K antagonist-naïve			Vitamin K antagonist-experienced		
	Warfarin	Dabigatran	Dabigatran	Warfarin	Dabigatran	Dabigatran
		110 mg	150 mg		110 mg	150 mg
Subjects, no.	1,825	793	646	1,918	547	412
Age, years						Y
Median	76	83	69	75	82	70
Interquartile range	69-82	78-87	64-74	69-82	78-86	65-74
Age $\geq$ 65 yrs, %	84.9	96.1	70.0	85.5	97.3	74.8
Age $\geq$ 75 yrs, %	52.9	82.8	18.6	51.3	84.8	20.9
Female sex, %	44.0	56.2	35.9	38.7	55.0	38.8
Risk scores at baseline						
CHADS <sub>2</sub> , mean (SD) <sup>a</sup>	3.15 (0.90)	3.41 (0.79)	2.64 (0.74)	3.19 (0.92)	3.51 (0.79)	2.91 (0.92)
CHA <sub>2</sub> DS <sub>2</sub> VASc, mean (SD) <sup>b</sup>	4.76 (1.40)	5.22 (1.14)	3.87 (1.19)	4.71 (1.33)	5.35 (1.11)	4.34 (1.31)
HAS-BLED, mean (SD) <sup>c</sup>	3.11 (1.04)	3.18 (0.89)	2.72 (1.00)	2.81 (0.96)	2.99 (0.95)	2.72 (0.99)
Comorbidities at baseline						
Prior ischemic stroke	75.3	81.2	74.9	75.7	82.1	76.5
Prior transient ischemic attack	36.3	32.0	35.8	37.2	32.4	34.7
Prior bleeding, %	16.2	20.9	13.0	19.2	24.5	19.7
Diabetes, %	16.1	15.4	13.0	18.0	14.1	20.6
Hypertension, %	36.4	33.0	29.6	37.7	36.7	38.1
Abnormal renal function, %	9.5	3.9	0.9	6.0	3.3	3.2
Abnormal hepatic function, %	0.4	0.8	0.0	0.1	0.5	0.0
Prior congestive heart failure, %	9.8	10.2	2.9	11.8	15.5	11.7
Prior myocardial infarction,						
unstable angina						
or cardiac arrest ,%	17.6	17.5	8.4	19.8	25.0	22.1
	)					
Medications at baseline						
Aspirin, %	43.0	42.7	34.8	23.0	25.6	21.8
Clopidogrel, %	21.4	20.1	20.3	3.0	6.4	5.8
NSAID, %	5.2	4.2	4.8	4.3	4.4	4.9
Clopidogrel and aspirin/NSAID,		<b>6 0</b>	5.0	0.4	2.0	1.5
Clopidogrei and aspirin/NSAID,	7.7	6.2	5.0	0.4	2.0	1.5


% <sup>a</sup>·CHADS<sub>2</sub>: score ranging from 0-5 which reflect the stroke risk in atrial fibrillation patients not in anticoagulant therapy (see Supplementary Table 2). <sup>b</sup>·CHA<sub>2</sub>DS<sub>2</sub>VASc: score ranging from 0-9 which reflect the risk of stroke in atrial fibrillation patients not in anticoagulant therapy (see Supplementary Table 2). <sup>c</sup>·HAS-BLED: score ranging from 0-9

which reflect the risk of bleeding in atrial fibrillation patients undergoing anticoagulant therapy (see Supplementary Table 2). Abbreviation: SD = Between-subjects standard deviation, NSAID = Non-steroidal anti-inflammatory drugs


# Table 2. Event rates and Cox hazard ratios for the various endpoints, according to VKA-experience stratum and current treatment.

	No.	Rate,	Crude hazard ratio	Adjusted <sup>a</sup> hazard	
	events	% per year	(95% CI)	ratio	
Vitamin K antagonist-naïve stratum					
Stroke or transient ischemic attack					
Warfarin	300	18.0	1 (reference)	1 (reference)	
Dabigatran 110mg	93	14.0	0.74 (0.59-0.93)	0.67 (0.52-0.86)	
Dabigatran 150mg	102	18.2	0.99 (0.78-1.24)	1.02 (0.80-1.30)	
Stroke					
Warfarin	231	13.4	1 (reference)	1 (reference)	
Dabigatran 110mg	82	12.2	0.85 (0.67-1.10)	0.74 (0.56-0.97)	
Dabigatran 150mg	82	14.1	1.02 (0.79-1.31)	1.10 (0.83-1.44)	
Transient ischemic attack					
Warfarin	84	4.6	1 (reference)	1 (reference)	
Dabigatran 110mg	17	2.4	0.49 (0.29-0.83)	0.48 (0.28-0.83)	
Dabigatran 150mg	25	4.0	0.85 (0.55-1.34)	0.79 (0.49-1.28)	
Vitamin K antagonist-experienced					
stratum					
Stroke or transient ischemic attack					
Warfarin	133	5.9	1 (reference)	1 (reference)	
Dabigatran 110mg	59	10.8	1.77 (1.30-2.40)	1.54 (1.11-2.13)	
Dabigatran 150mg	45	9.2	1.57 (1.12-2.19)	1.79 (1.25-2.56)	
Stroke	) '				
Warfarin	102	4.5	1 (reference)	1 (reference)	
Dabigatran 110mg	52	9.4	2.03 (1.45-2.84)	1.73 (1.21-2.47)	
Dabigatran 150mg	33	6.6	1.49 (1.00-2.20)	1.79 (1.18-2.72)	
Transient ischemic attack					
Warfarin	39	1.7	1 (reference)	1 (reference)	
Dabigatran 110mg	14	2.4	1.42 (0.77-2.62)	1.30 (0.68-2.5+)	
Dabigatran 150mg	15	2.9	1.73 (0.95-3.14)	1.72 (0.92-3.22)	

<sup>a</sup> Estimates adjusted for: CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED components (binary); age (cubic spline); months since august 2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline). Abbreviation: CI = confidence interval.



\*Prior hospital diagnosis of mitral stenosis; venous thromboembolism; valvular surgery; or prior phenprocoumon use. Abbreviations: VKA: Vitamin K antagonist



	International Classification of Diseases 10th revision (ICD-10) code	Anatomical Therapeutic Chemical (ATC) code
Condition		
Congestive heart failure	I11.0; I13.0; I13.2; I42.0; I50	and C03C
Left ventricular dysfunction	150.1; 150.9	
Hypertension		See specified definition <sup>a</sup>
Diabetes mellitus	E10.0; E10.1; E10.9; E11.0; E11.1; E11.9	or A10
Ischemic stroke	I63; I64.9	
Systemic embolism	I74	
Transient ischemic attack	G45	
Aortic plaque	170.0	)
Peripheral arterial disease	170.2-170.9; 171; 173.9	
Myocardial infarction	I21-I23	
Unstable angina	120	
Cardiac arrest	I46	
Abnormal renal function	112; 113; N00-N05; N07; N11; N14; N17-N19; Q61	
Abnormal hepatic function	B15.0; B16.0; B16.2; B19.0; K70.4; K72; K76.6; I85	
Bleeding	I60-I62; D62; J94.2; H11.3; H35.6; H43.1; N02; N95; R04; R31; R58; K25.0; K26.0; K27.0; K28.0; K29.0; S06.3C; S06.4; S06.5; S06.6	
Alcohol intake	E22.4; E52.9A; F10; G31.2; G62.1; G72.1; I42.6; K29.2; K70; K86.0; L27.8A; O35.4M; T51; Z71.4; Z72.1	
Atrial fibrillation	I48	
Medication		
Dabigatran		B01AE07
Warfarin		B01AA03
Aspirin		B01AC06
Clopidogrel		B01AC04
Phenprocoumon		B01AA04
Non-steroidal anti-inflammatory drugs		M01A

Supplementary Table 1. ICD-10/ATC-codes used to identify comorbid conditions and comedication

<sup>a</sup>We identified subjects with hypertension from combination treatment with at least two of the following classes of antihypertensive drugs:

I. Alpha adrenergic blockers (C02A, C02B, C02C)

II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52) III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)

IV. Beta blockers (C07)

V. Calcium channel blockers (C07F, C08, C09BB, C09DB)

VI. Renin-angiotensin system inhibitors (C09).

Risk score	Points if present
CHADS <sub>2</sub> <sup>a</sup>	n present
Congestive heart failure	1
Hypertension	1
Age $\geq 65$ years	1
Diabetes mellitus	1
Stroke (ischemic stroke or transient ischemic attack,)	2
CHA <sub>2</sub> DS <sub>2</sub> VASc <sup>b</sup>	
Congestive heart failure or Left Ventricular Dysfunction	1
Hypertension	1
Age $\geq 65$ years	1
Age $\geq$ 75 years	1
Diabetes mellitus	1
Stroke (ischemic stroke, transient ischemic disease or systemic embolism)	2
Vascular disease (myocardial infarction, peripheral arterial disease, or aortic plaque)	1
Sex category (female)	1
HAS-BLED <sup>c</sup>	
Hypertension	1
Abnormal renal function	1
Abnormal hepatic function	1
Stroke (ischemic stroke or transient ischemic attack)	1
Bleeding	1
Labile international normalized ratio <sup>d</sup>	1
Elderly age ( $\geq 65$ years)	1
Drugs (aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs)	1
Alcohol intake	1

#### Supplementary Table 2. Definition of risk scores.

<sup>a</sup>Reflects stroke risk in atrial fibrillation patients not in anticoagulant therapy (Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110(16):2287-92)

<sup>d</sup>Not included due to unavailable information

<sup>&</sup>lt;sup>b</sup>Reflects stroke risk in atrial fibrillation patients not in anticoagulant therapy (Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72)

<sup>&</sup>lt;sup>c</sup>Reflects bleeding risk in atrial fibrillation patients undergoing anticoagulant therapy (Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100)

Supplementary Table 3. Persistence-adjusted (censoring participants at the time of nonpersistence) event rates and Cox hazard ratios for the various endpoints, according to VKAexperience stratum and current treatment.

	No. events	Rate, % per year	Crude hazard ratio (95% CI)	Adjusted <sup>a</sup> hazard ratio (95% CI)
Vitamin K antagonist-naïve stratum				
Stroke or transient ischemic attack				
Warfarin	223	23.2	1 (reference)	1 (reference)
Dabigatran 110mg	69	17.2	0.73 (0.56-0.95)	0.69 (0.52-0.92)
Dabigatran 150mg	84	23.9	1.08 (0.84-1.39)	1.13 (0.86-1.49)
Stroke				
Warfarin	174	17.7	1 (reference)	1 (reference)
Dabigatran 110mg	60	14.8	0.82 (0.61-1.09)	0.75 (0.55-1.03)
Dabigatran 150mg	66	18.1	1.08 (0.81-1.43)	1.19 (0.87-1.61)
Transient ischemic attack		1011		
Warfarin	55	5.3	1 (reference)	1 (reference)
Dabigatran 110mg	11	2.6	0.48 (0.25-0.91)	0.50 (0.26-0.96)
Dabigatran 150mg	21	5.4	1.06 (0.64-1.77)	0.94 (0.55-1.63)
Vitamin K antagonist-experienced stratum				
Stroke or transient ischemic attack				
Warfarin	95	6.8	1 (reference)	1 (reference)
Dabigatran 110mg	41	12.9	1.82 (1.26-2.63)	1.5 (1.01-2.23)
Dabigatran 150mg	28	10.3	1.49 (0.98-2.27)	1.67 (1.07-2.61)
Stroke	y 20	10.5	1.19 (0.90 2.27)	1.07 (1.07 2.01)
Warfarin	73	5.2	1 (reference)	1 (reference)
Dabigatran 110mg	35	11.0	2.03 (1.36-3.04)	1.59 (1.03-2.45)
Dabigatran 150mg	21	7.6	1.44 (0.89-2.34)	1.81 (1.08-3.04)
Transient ischemic attack	<b>2</b> ±	,	2.11 (0.02 2.5 1)	
Warfarin	23	1.6	1 (reference)	1 (reference)
Dabigatran 110mg	9	2.7	1.64 (0.76-3.55)	1.59 (0.69-3.69)
Dabigatran 150mg	8	2.8	1.71 (0.76-3.81)	1.41 (0.61-3.26)

<sup>a</sup>Estimates adjusted for: CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED components (binary); age (cubic spline); months since august 2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline)

Abbreviations: CI = confidence interval

Supplementary Table 4. Event rates and Cox hazard ratios for the various endpoints, requiring endpoints to have been registered as the primary diagnosis in connection with hospitalization for at least one night, according to VKA-experience stratum and current treatment.

	No. events	Rate, % per year	Crude hazard ratio (95% CI)	Adjusted <sup>a</sup> hazard ratio (95% CI)
Vitamin K antagonist-naïve stratum				
Stroke or transient ischemic attack				
Warfarin	97	5.3	1 (reference)	1 (reference)
Dabigatran 110mg	33	4.6	0.84 (0.56-1.25)	0.69 (0.46-1.03)
Dabigatran 150mg	23	3.6	0.67 (0.43-1.06)	0.77 (0.48-1.25)
Stroke				
Warfarin	66	3.5	1 (reference)	1 (reference)
Dabigatran 110mg	26	3.6	0.98 (0.62-1.54)	0.71 (0.45-1.13)
Dabigatran 150mg	12	1.9	0.51 (0.28-0.95)	0.62 (0.32-1.19)
Transient ischemic attack				
Warfarin	36	1.9	1 (reference)	1 (reference)
Dabigatran 110mg	9	1.2	0.62 (0.30-1.27)	0.61 (0.30-1.24)
Dabigatran 150mg	12	1.9	0.95 (0.49-1.83)	0.99 (0.50-1.98)
Vitamin K antagonist-experienced stratum				
Stroke or transient ischemic attack	$\langle \rangle \rangle$			
Warfarin	59	2.6	1 (reference)	1 (reference)
Dabigatran 110mg	31	5.5	2.10 (1.36-3.25)	1.49 (0.94-2.36)
Dabigatran 150mg	20	3.9	1.53 (0.92-2.53)	2.08 (1.20-3.59)
Stroke		• •		
Warfarin	32	1.4	1 (reference)	1 (reference)
Dabigatran 110mg	23	4.0	2.85 (1.67-4.88)	1.83 (1.04-3.21)
Dabigatran 150mg	11	2.1	1.55 (0.78-3.07)	2.71 (1.28-5.77)
Transient ischemic attack			(	
Warfarin	30	1.3	1 (reference)	1 (reference)
Dabigatran 110mg	9	1.6	1.20 (0.57-2.53)	1.04 (0.47-2.30)
Dabigatran 150mg	10	1.9	1.48 (0.72-3.03)	1.50 (0.71-3.19)

<sup>a</sup>Estimates adjusted for: CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED components (binary); age (cubic spline); months since august 2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline)

Abbreviations: CI = confidence interval

Supplementary Table 5. Event rates and Cox hazard ratios for the various endpoints, according to VKA-experience stratum and current treatment, among atrial fibrillation patients with no history of stroke or transient ischemic attack.

	Vitamin K antagonist-naïve			Vitamin K	perienced	
	Warfarin	Dabigatran 110 mg	Dabigatran 150 mg	Warfarin	Dabigatran 110 mg	Dabigatran 150 mg
Subjects, no.	9,216	2,236	3,363	6,018	1,484	1,797
Age, yrs						
Median	72	81	67	74	-81	68
Interquartile range	65-79	76-86	62-72	67-80	76-85	64-73
Female sex, %	41.4	54.7	36.7	37.9	54	34.4
Risk scores at baseline						
HAS-BLED, mean (SD)	0.96 (0.88)	1.38 (0.82)	0.61 (0.74)	1.16 (0.90)	1.54 (0.87)	0.91 (0.86)
CHADS <sub>2</sub> , mean (SD)	2.41 (1.43)	3.15 (1.17)	1.78 (1.19)	2.61 (1.33)	3.35 (1.20)	2.19 (1.28)
CHA <sub>2</sub> DS <sub>2</sub> VASc, mean (SD)	1.73 (1.06)	2.01 (0.90)	1.50 (1.02)	1.66 (0.91)	1.94 (0.87)	1.63 (1.00)
Stroke or transient ischemic attack during following No. events	194	56	55	98	49	21
Rate, % per year	2.0	2.7	1.7	1.2	3.1	0.9
Crude estimates	2.0	2.1	F./	1.2	5.1	0.9
Hazard ratio 95% confidence interval	1 (reference)	1.31 0.97-1.77	0.83 0.61-1.13	1 (reference)	2.47 1.75-3.48	0.75 0.47-1.2
Adjusted <sup>a</sup> estimates						
Hazard ratio 95% confidence interval	1 (reference)	0.99 0.72-1.36	1.05 0.76-1.45	1 (reference)	1.73 1.2-2.48	1.04 0.64-1.7

<sup>a</sup>Estimates adjusted for: CHA<sub>2</sub>DS<sub>2</sub>VASc and HAS-BLED components (binary); age (cubic spline); months since august 2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline)

CHADS<sub>2</sub>: score ranging from 0-5 which reflect the stroke risk in atrial fibrillation patients not in anticoagulant therapy (see Supplementary Table 2).

 $CHA_2DS_2VASc$ : score ranging from 0-9 which reflect the risk of stroke in atrial fibrillation patients not in anticoagulant therapy (see Supplementary Table 2).

HAS-BLED: score ranging from 0-9 which reflect the risk of bleeding in atrial fibrillation patients undergoing anticoagulant therapy (see Supplementary Table 2).

SD: Between-subjects standard deviation

#### **Clinical Significance**

This study revealed, that in clinical practice, vitamin K antagonist-experienced patients with a history of stroke or transient ischemic attack who switch to dabigatran therapy may have an increased rate of a recurrent stroke compared to patients persisting with vitamin K antagonist therapy.

other the series